John Xie

4.2k total citations · 1 hit paper
46 papers, 1.7k citations indexed

About

John Xie is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, John Xie has authored 46 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Surgery and 15 papers in Oncology. Recurrent topics in John Xie's work include Lung Cancer Treatments and Mutations (15 papers), Diabetes Treatment and Management (14 papers) and Pancreatic function and diabetes (11 papers). John Xie is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Diabetes Treatment and Management (14 papers) and Pancreatic function and diabetes (11 papers). John Xie collaborates with scholars based in United States, South Korea and Japan. John Xie's co-authors include Gary Meininger, Lawrence A. Leiter, Dainius Balis, William Canovatchel, Pablo Arias, Kun‐Ho Yoon, William T. Cefalu, Leo Niskanen, Keith Usiskin and David Polidori and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

John Xie

41 papers receiving 1.7k citations

Hit Papers

Efficacy and safety of canagliflozin versus glimepiride i... 2013 2026 2017 2021 2013 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
    2013 606 citations William T. Cefalu, Lawrence A. Leiter et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Xie United States 17 1.2k 656 614 252 249 46 1.7k
Frans Van de Werf Belgium 8 1.9k 1.6× 733 1.1× 666 1.1× 267 1.1× 91 0.4× 16 2.3k
Samuel S. Engel United States 5 1.7k 1.4× 654 1.0× 549 0.9× 246 1.0× 67 0.3× 6 1.9k
Thomas Idorn Denmark 19 1.6k 1.3× 498 0.8× 645 1.1× 367 1.5× 169 0.7× 44 2.1k
Nima Soleymanlou Canada 16 2.1k 1.7× 693 1.1× 1.3k 2.1× 241 1.0× 248 1.0× 27 3.0k
Heidrun Bosch‐Traberg Denmark 14 1.2k 1.0× 462 0.7× 425 0.7× 286 1.1× 102 0.4× 25 1.5k
Shuo‐Meng Wang Taiwan 24 809 0.7× 180 0.3× 989 1.6× 65 0.3× 278 1.1× 94 1.7k
Sanbao Chai China 17 582 0.5× 289 0.4× 212 0.3× 151 0.6× 64 0.3× 49 935
Fernando J. Lavalle‐González Mexico 17 948 0.8× 326 0.5× 374 0.6× 101 0.4× 41 0.2× 70 1.3k
Egon Pfarr Germany 15 1.4k 1.1× 488 0.7× 571 0.9× 109 0.4× 361 1.4× 25 1.8k
Fritz Hoppichler Austria 15 741 0.6× 294 0.4× 1.3k 2.1× 120 0.5× 99 0.4× 27 2.1k

Countries citing papers authored by John Xie

Since Specialization
Citations

This map shows the geographic impact of John Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Xie more than expected).

Fields of papers citing papers by John Xie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Xie. The network helps show where John Xie may publish in the future.

Co-authorship network of co-authors of John Xie

This figure shows the co-authorship network connecting the top 25 collaborators of John Xie. A scholar is included among the top collaborators of John Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Xie. John Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leighl, Natasha B., José Trigo, Keunchil Park, et al.. (2025). Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer. Lung Cancer. 205. 108579–108579. 1 indexed citations
2.
Haddish‐Berhane, Nahor, Alberto Russu, Meena Thayu, et al.. (2023). Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer. Clinical Pharmacology & Therapeutics. 115(3). 468–477. 5 indexed citations
3.
4.
5.
Park, Keunchil, Joshua K. Sabari, Eric B. Haura, et al.. (2022). MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study. Annals of Oncology. 33. S482–S482. 1 indexed citations
6.
7.
Xie, John, et al.. (2021). Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.. SHILAP Revista de lepidopterología. 15. 100247–100247. 6 indexed citations
8.
Shreeve, S. Martin, Remy B. Verheijen, John Xie, et al.. (2021). P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC. Journal of Thoracic Oncology. 16(3). S620–S621. 12 indexed citations
9.
Cho, Byoung Chul, Dongwook Kim, Jin Sun Lee, et al.. (2020). 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Annals of Oncology. 31. S813–S813. 32 indexed citations
10.
11.
Blonde, Lawrence, Kaj Stenlöf, Albert Fung, et al.. (2016). Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine. 128(4). 371–380. 55 indexed citations
12.
Qiu, Rong, Dainius Balis, George Capuano, John Xie, & Gary Meininger. (2016). Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes Therapy. 7(4). 659–678. 7 indexed citations
13.
Mohan, Viswanathan, Bipin Sethi, Ganapathi Bantwal, et al.. (2016). Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Indian Journal of Endocrinology and Metabolism. 20(3). 372–372. 18 indexed citations
14.
Qiu, Rong, Dainius Balis, John Xie, et al.. (2016). Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Current Medical Research and Opinion. 33(3). 553–562. 27 indexed citations
15.
Leiter, Lawrence A., Thomas Först, David Polidori, et al.. (2015). Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes & Metabolism. 42(1). 25–32. 101 indexed citations
16.
Weir, Matthew R., Irina Kline, John Xie, Robert Edwards, & Keith Usiskin. (2014). Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Current Medical Research and Opinion. 30(9). 1759–1768. 96 indexed citations
17.
Cefalu, William T., Lawrence A. Leiter, Kun‐Ho Yoon, et al.. (2013). Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. The Lancet. 382(9896). 941–950. 606 indexed citations breakdown →
18.
Xie, John, et al.. (2007). An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Supportive Care in Cancer. 15(12). 1385–1392. 5 indexed citations
19.
Gregory, Stephanie A., et al.. (2007). An Extended Dosing Regimen of Epoetin Alfa 60,000 Units Every 2 Weeks in Anemic Patients with Cancer Receiving Chemotherapy. PubMed. 4(4). 225–232. 1 indexed citations
20.
Henry, David H., Lucio Gordan, Veena Charu, et al.. (2006). Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Current Medical Research and Opinion. 22(7). 1403–1413. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frans Van de Werf Breakdown of academic impact, for papers by Samuel S. Engel Breakdown of academic impact, for papers by Thomas Idorn Breakdown of academic impact, for papers by Nima Soleymanlou Breakdown of academic impact, for papers by Heidrun Bosch‐Traberg Breakdown of academic impact, for papers by Shuo‐Meng Wang Breakdown of academic impact, for papers by Sanbao Chai Breakdown of academic impact, for papers by Fernando J. Lavalle‐González Breakdown of academic impact, for papers by Egon Pfarr Breakdown of academic impact, for papers by Fritz Hoppichler
Rankless by CCL
2026